Close
GMP
FDA Academy
Downloadables
Bids and Awards
Careers
FAQs
Report
Contact Us
Menu
GMP
FDA Academy
Downloadables
Bids and Awards
Careers
FAQs
Report
Contact Us
Facebook
Search
Home
About FDA
Transparency
Issuances
Advisories
Administrative Order
Executive Order
FDA Circular
FDA Memorandum
Memorandum Circular
Republic Act
Old Issuances
Services
eServices
ePortal
ePortal2
Doctrack
RRDportal
Menu
Home
About FDA
Transparency
Issuances
Advisories
Administrative Order
Executive Order
FDA Circular
FDA Memorandum
Memorandum Circular
Republic Act
Old Issuances
Services
eServices
ePortal
ePortal2
Doctrack
RRDportal
ChAdOx1-S[recombinant] VAXZEVRIA (COVID-19 Vaccine AstraZeneca)
On 28 January 2021, the Food and Drug Administration (FDA)
issued authorization (amended on 10 March 2022) granting AstraZeneca Pharmaceuticals (Phils.) Inc. the emergency use approval of COVID-19 vaccine ChAdOx1-S[recombinant] Vaxzevria (COVID-19 Vaccine AstraZeneca).
Product Information
Patient Information Leaflet
For more information on reporting side effects, click
here
.
Shares